Protagenic Therapeutics, Incnew 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Protagenic Therapeutics, Inc. filed its Form 10-K for the fiscal year ended March 31, 2026, detailing clinical trial progress for PT00114, but also announcing its delisting from Nasdaq and ongoing financial challenges.
OQB
Protagenic Therapeutics, Inc. files its annual report on Form 10-K, detailing its financial results for the year ended December 31, 2024, and providing an update on its clinical development programs and corporate strategy.
OQB
Protagenic Therapeutics has filed an amendment to its annual report, highlighting the correction of an error and providing updates on its clinical trial progress for PT00114.
OQB
10-K/A: Protagenic Therapeutics Files Amended 10-K to Correct Omission, Reports on Clinical Trial Progress
Protagenic Therapeutics files an amendment to its annual report to include an omitted certification, while also providing updates on its clinical trial progress and financial status.
OQB
Protagenic Therapeutics' annual 10-K filing details its capital structure, ongoing clinical trials, and strategic focus on developing treatments for stress-related neuropsychiatric disorders.